Skip to content

Thyroid Eye Disease: Subcutaneous Elegrobart Reduced Eye Bulging in a Phase 3 Trial

Thyroid eye disease (TED) can make the eyes look bulging, cause double vision, and disrupt daily life. At AAO 2026, Michael T. Yen, MD, of Baylor College of Medicine reviewed phase 3 REVEAL-1 results for elegrobart, an investigational medicine that targets the IGF-1 receptor and is given under the skin rather than by IV infusion.

Why delivery route matters

Current IGF-1R monoclonal antibodies used for TED typically require intravenous infusion. Yen noted that a subcutaneous option could lower treatment burden by reducing infusion-center visits and long chair time, and that a different peak drug level might change the side-effect profile. Elegrobart remains investigational for this use and is not presented here as a treatment we offer.

What REVEAL-1 showed

REVEAL-1 (NCT06812325) randomized 132 patients with active TED 1:1:1 to elegrobart every 4 weeks, elegrobart every 8 weeks, or placebo.

  • Both dosing schedules significantly improved proptosis (eye protrusion) versus placebo, with more than 2 mm mean reduction reported in the treatment arms.
  • Diplopia improved in about 70% of the every-4-week group, and more than half had complete resolution of double vision in that arm, according to Yen’s report.
  • Hearing-related symptoms remain a focus for this drug class. Yen estimated tinnitus-type hearing impairment symptoms in roughly 12–14% on every-4-week dosing and under 10% on every-8-week dosing; Viridian reported placebo-adjusted rates of 11.3% and 2.3%.

Neutral education, not a sales pitch

Khanna Vision Institute does not provide oculoplastic or orbital specialty care for TED. If an exam suggests thyroid eye disease, we refer to an oculoplastics or thyroid-eye specialist and help with the handoff. Warning signs that deserve prompt evaluation include progressive bulging, new double vision, eye-movement pain, or vision that dims when you look up.

What patients can do now

  • Keep thyroid levels under the care of an endocrinologist.
  • Stop smoking; smoking worsens TED.
  • Use lubricating drops for surface irritation and elevate the head of the bed if lids do not close fully at night.
  • Ask about imaging and visual-field testing if optic-nerve compression is a concern.

For broader aging-eye education while you coordinate specialty care, see bettereyesightatanyage.com.

Source: AAO 2026: Elegrobart reduces proptosis in active thyroid eye disease (Ophthalmology Times, 10/11/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.